Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Current Assets (2020 - 2023)

Historic Current Assets for Cullinan Therapeutics (CGEM) over the last 4 years, with Q3 2023 value amounting to $476.7 million.

  • Cullinan Therapeutics' Current Assets fell 1810.13% to $476.7 million in Q3 2023 from the same period last year, while for Sep 2023 it was $476.7 million, marking a year-over-year decrease of 1810.13%. This contributed to the annual value of $474.5 million for FY2022, which is 5998.97% up from last year.
  • As of Q3 2023, Cullinan Therapeutics' Current Assets stood at $476.7 million, which was down 1810.13% from $498.2 million recorded in Q2 2023.
  • Cullinan Therapeutics' 5-year Current Assets high stood at $622.8 million for Q2 2022, and its period low was $212.3 million during Q4 2020.
  • For the 4-year period, Cullinan Therapeutics' Current Assets averaged around $417.1 million, with its median value being $423.2 million (2021).
  • Data for Cullinan Therapeutics' Current Assets shows a peak YoY increase of 8081.3% (in 2022) and a maximum YoY decrease of 2794.16% (in 2022) over the last 5 years.
  • Quarter analysis of 4 years shows Cullinan Therapeutics' Current Assets stood at $212.3 million in 2020, then surged by 39.71% to $296.6 million in 2021, then skyrocketed by 59.99% to $474.5 million in 2022, then rose by 0.47% to $476.7 million in 2023.
  • Its Current Assets stands at $476.7 million for Q3 2023, versus $498.2 million for Q2 2023 and $399.0 million for Q1 2023.